November 23, 2017 |
New Drug Proving Effective in Attacking Advanced Prostate Cancer
June 21, 2013  | 

INDIANAPOLIS – Franciscan St. Francis Health Cancer Center is using a new drug to treat men with advanced prostate cancer.

It’s called Xofigo® (radium Ra 223 dichloride), a radiopharmaceutical used in patients with late-stage, metastatic disease that has spread to the bones. It recently was approved for use by the U.S. Food and Drug Administration.

As prostate cancer progresses to advanced stages it may become castration-resistant, which has become resistant to medical or surgical treatments that lower testosterone. About 90 percent of men with advanced prostate cancer will develop bone metastases.

“Most men with castration-resistant prostate cancer develop bone metastases, which can decrease overall survival,” said Michael Eaton, MD, PhD, radiation oncologist, who performed the procedure. “Xofigo has actually demonstrated an ability to extend survival compared to existing treatment options.”

A phase III ALSYMPCA clinical trial, involving 809 patients with symptomatic castration-resistant prostate cancer that spread to bones but not other organs, showed a 2.8 months increase in median overall survival due to the drug as compared to placebo. The extended survival time figures are only for validation of effectiveness in the clinical trial using a limited number of treatments. Longer survival time is assumed for patients who respond well to Xofigo, receive longer periods of treatment or start the treatment in an earlier stage of the disease than in the trial. Continue>

Page | 1 2
Suggested Articles